GHK-Cu Under-Eye Research: Finkley 2005 Periorbital Data & Why Eyelid Skin Responds Differently (UAE 2026 Guide)

Why the Under-Eye Is a Different Tissue Entirely

If you treat the periorbital area like the rest of the face, you will misread your data. Eyelid and immediately sub-orbital skin differ from cheek skin in five measurable ways, and each one changes how GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II)) behaves once applied.

• Thickness. Eyelid skin averages 0.3–0.5 mm; cheek skin averages 1.8–2.1 mm. The diffusion path is roughly a quarter of the length.
• Stratum corneum. Periorbital stratum corneum is thinner with fewer corneocyte layers, lowering the principal penetration barrier.
• Sebaceous gland density. Lower than the rest of the face — less sebum buffering of hydrophilic peptides.
• Capillary density. Higher, especially in the lower eyelid pretarsal region — faster systemic clearance of penetrant copper peptide.
• Mechanical loading. 10,000–20,000 blinks per day plus high facial expressivity around orbicularis oculi — collagen turnover signals are constantly retriggered.

The combination matters: a peptide that gets in fast, gets cleared fast, and lands in tissue that is constantly remodelling will show different kinetics from the same peptide on a cheek. This is why eye-area data deserves its own protocol.

Finkley 2005 — The Foundational Periorbital Study

The Finkley et al. 2005 trial in the International Journal of Cosmetic Science evaluated a GHK-Cu eye cream in 67 women aged 50–59 over 12 weeks, twice-daily application. Endpoints included fine lines (silicone-replica imaging), skin density (ultrasound), skin thickness, and self-assessment scores. It remains the most-cited published periorbital GHK-Cu dataset.

Headline endpoints

The Finkley dataset is important for two reasons. First, it used objective imaging endpoints — ultrasound and replica analysis — not just subjective assessment. Second, it ran for the full 12 weeks needed to capture matrix remodelling rather than early plumping from hydration alone. Earlier Pickart-era work had established copper-peptide tissue effects; Finkley translated those into the specific periorbital application format that most subsequent eye-cream research has followed.

The Pickart Mechanism — Why Copper Pairs With This Tripeptide

The mechanistic case for GHK-Cu has been built across four decades by Pickart and colleagues. The peptide itself, glycyl-histidyl-lysine, was isolated from human plasma in 1973. The copper(II) ion binds tightly to the histidyl-lysine motif and forms a complex that does what neither component does alone:

1. Upregulates type I collagen synthesis in dermal fibroblasts (Pickart 2012, BioMed Research International).
2. Increases decorin expression — a small proteoglycan that organises collagen fibril spacing, partially responsible for the density signal on ultrasound.
3. Modulates matrix metalloproteinases. GHK-Cu shifts the MMP/TIMP balance toward controlled remodelling rather than net breakdown.
4. Promotes angiogenesis and wound granulation tissue — the same pathway responsible for the early dermal-repair use case Pickart documented in pressure ulcer and diabetic wound trials.
5. Acts as a copper-delivery system. The tripeptide chaperone allows controlled copper entry into cells without the toxicity of free Cu(II).

For periorbital research, the decorin and collagen-density mechanisms map directly onto Finkley's ultrasound findings. The increased echogenicity is consistent with denser, better-organised dermal matrix — not just oedema.

Why Eyelid Tissue Responds Faster — And Sometimes Backfires

The same thinness that makes the eye area a strong responder also makes it a strong over-responder. Three failure modes appear repeatedly in periorbital GHK-Cu research:

1. Dose-density miscalibration

A 4 mg/mL formula applied generously to the cheek delivers a tolerable copper-peptide dose per cm². The same volume applied to the much smaller eye-area surface concentrates the dose. Researchers consistently under-dilute for the eye area. The published periorbital range sits at 2–4 mg/mL with a strict 0.05–0.1 mL per eye dose.

2. Vehicle migration onto conjunctiva

Eye-area formulas must be tested for migration. A vehicle that creeps into the tear film carries copper into a tissue that does not need it and can react with mild stinging or transient redness. Stable emulsions and high-viscosity gels reduce migration. Avoid oil-rich vehicles that liquefy at lid temperature.

3. Stacking with retinoids or acids

Periorbital protocols frequently fail because researchers stack GHK-Cu with tretinoin or glycolic acid on the same skin in the same evening. Acidic conditions destabilise the copper complex; retinoid-thinned stratum corneum further amplifies copper exposure. Separate them — GHK-Cu in the morning, retinoid at night, never the same hour on the eye area.

Periorbital Imaging Endpoints Researchers Should Track

If you are running an in-house periorbital protocol, the published endpoint stack from Finkley 2005 and the supporting Leyden / Pickart literature gives you a defensible set of measures. Don't rely on photography alone — periorbital change is subtle and lighting-sensitive.

• 20 MHz B-mode ultrasound — gold standard for dermal density and thickness. Bedside-portable units are now reasonably priced.
• Silicone replica + image analysis — quantitative fine-line scoring. Reproducible if the replica protocol is standardised.
• Cutometer skin elasticity (R2 / R7 ratios) — captures the firmness signal subjects report.
• Standardised photography with fixed lighting, expression-controlled. VISIA or equivalent is ideal but not essential.
• Subject-reported outcomes — useful as a secondary endpoint, not a primary.

Protocol Comparison — Periorbital Approaches in the Published Record

Where to Buy GHK-Cu in the UAE — REVIVE LAB Dubai Stock & 24h Delivery

This is the buyer-intent section. If you reached this page because you want to order GHK-Cu in the UAE quickly, here is the operational detail. REVIVE LAB holds GHK-Cu 50 mg and 100 mg lyophilised vials in Dubai stock and ships across all seven emirates with 24h delivery.

UAE delivery windows by emirate

Why same-day Dubai dispatch matters for copper peptide research

• Cold-chain integrity. Lyophilised GHK-Cu is stable at room temperature for short windows but degrades faster with heat exposure. UAE ambient temperature in June–September makes courier transit time the principal risk variable. Same-day delivery keeps that window under 6 hours.
• Reconstitution timing. Researchers who plan to reconstitute on receipt benefit from predictable arrival windows. REVIVE provides SMS arrival confirmations.
• HPLC certificate of analysis ships with every vial of GHK-Cu — verify identity and purity before opening.
• Sharjah and northern emirates next-day windows are met via insulated couriers maintaining the 2–8°C envelope for at least 36 hours.

Ordering process

1. Select strength on the GHK-Cu product page — 50 mg vials suit topical research formulations; 100 mg vials suit larger or repeated batch work.
2. Add bacteriostatic water (3 mL vials) if you need reconstitution diluent.
3. Choose Dubai same-day or standard 24h UAE-wide delivery at checkout.
4. Payment via card or COD where available.
5. Cold-chain courier with arrival SMS — most Dubai orders arrive within 4–6 hours of cutoff.

See the broader REVIVE peptides UAE catalogue for the full stock list including Tesamorelin, Retatrutide, BPC-157 and TB-500.

Reconstitution For Periorbital Research Work

REVIVE supplies GHK-Cu as a sterile lyophilised powder in 50 mg and 100 mg vials. For periorbital research formulations:

• 50 mg vial + 25 mL of carrier = 2 mg/mL working solution (matches lower end of published periorbital range).
• 50 mg vial + 12.5 mL of carrier = 4 mg/mL working solution (matches upper end).
• 100 mg vial + 25 mL of carrier = 4 mg/mL (efficient for repeated batches).
• Carrier choice — bacteriostatic water for short-term research solutions; specialist cosmetic-research vehicles for stability work.
• Storage — refrigerate reconstituted solutions, protect from light, plan use within 14–28 days depending on vehicle.

Deeper guidance: see our GHK-Cu reconstitution guide and UAE peptide storage guide.

What the Published Record Does Not Yet Show

Honest research framing matters. The Finkley 2005 dataset is the strongest periorbital imaging-endpoint study in the published GHK-Cu literature, but several questions remain open:

• Head-to-head vs retinoids for the same periorbital endpoint set is limited.
• Optimal concentration within the 2–4 mg/mL range is not finely resolved.
• Long-term (24-month+) periorbital follow-up is sparse.
• Subcutaneous microdosing for skin density is an emerging research direction without the same imaging-endpoint depth as topical work.
• Combination protocols with copper peptide plus growth-factor systems remain mechanistically interesting but under-studied.

This is exactly the territory where in-house research protocols add value — and exactly why imaging endpoints, not just photos, matter.

Related Reading

For broader copper-peptide context see our GHK-Cu collagen mechanism explainer, the copper peptide vs retinoid comparison, and our UAE peptide storage guide. To compare with regenerative peptides used in research adjacent to skin healing, see the BPC-157 tendon healing post.